Last reviewed · How we verify
Zonisamide CR and Bupropion SR
Zonisamide CR and Bupropion SR is a Small molecule drug developed by Orexigen Therapeutics, Inc. It is currently in Phase 2 development.
At a glance
| Generic name | Zonisamide CR and Bupropion SR |
|---|---|
| Sponsor | Orexigen Therapeutics, Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zonisamide CR and Bupropion SR CI brief — competitive landscape report
- Zonisamide CR and Bupropion SR updates RSS · CI watch RSS
- Orexigen Therapeutics, Inc portfolio CI
Frequently asked questions about Zonisamide CR and Bupropion SR
What is Zonisamide CR and Bupropion SR?
Zonisamide CR and Bupropion SR is a Small molecule drug developed by Orexigen Therapeutics, Inc.
Who makes Zonisamide CR and Bupropion SR?
Zonisamide CR and Bupropion SR is developed by Orexigen Therapeutics, Inc (see full Orexigen Therapeutics, Inc pipeline at /company/orexigen-therapeutics-inc).
What development phase is Zonisamide CR and Bupropion SR in?
Zonisamide CR and Bupropion SR is in Phase 2.